Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well you know it worked for me
LMAO
Brittany L. Hartwell
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Roles: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing - original draft, and Writing - review & editing.
Present address: Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
https://cse.umn.edu/bme/brittany-hartwell
& unlike Ronnie she even has a twitter page LOL
https://twitter.com/Britt_Hartwell
Very excited to share that our new article is out this week in
@ScienceTM
-- & is featured on the cover! A fitting cap to #ICMI2022!
https://science.org/doi/10.1126/scitranslmed.abn1413
This work from my postdoc in the IrvineLab
@kochinstitute
@MIT
introduces an intranasal mucosal vaccine strategy that (1/)
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
SCIENCE TRANSLATIONAL MEDICINE
20 Jul 2022
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
https://www.science.org/doi/10.1126/scitranslmed.abn1413
and Harvard (to D.J.I.), the Bill & Melinda Gates Foundation (to J.C.L.), ... Immunization with HIV-1 gp41 subunit virosomes induces mucosal
Jesus is your attorney
Stay Positive, right
:}
I can, again. That's the point
Got to know how to make friends
Not my thing but again
Company doesn't seem to be doing that w/ us
I consider you my friend
& that's the point
If you want me to fill your 100K @ 0285 I can
:}
You know that b/c you don't do any DD
& your welcome
It isn't tongues
What I'm telling you friend is that the trades today
Don't equate to 6 or 7 bucks w/ or w/o the commissions
I'll tell you the difference Ronnie
It's not the day's gain or loss or the difference in the commissions
We don't care if it's thinly traded
The point is, do something about it, different than today
I still respect you but @ the point you become more of a bore than me.
I won't
Hey Ronnie, once you get it updated
What's the difference in the day that you can't possibly figure out
6 or 7 bucks
Why would it matter, sport ?
Funny how when it doesn't fit
What did the good doctor do here exactly b/c we are all waiting on you to explain the difference in Google or Apple here, not.
This is yuge news today
ETH Zurich
Gonna blow everyone's minds
LOL
When will everyone be buying ?
ROTFLOL
*The previously reported efforts to finance a Ph II clinical trial in head and neck cancer did not, under the current market conditions, result in a feasible way forward and PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology
PCI Biotech: Invitation to first-half year 2022 results presentation
https://markets.ft.com/data/announce/detail?dockey=1330-1000711985en-7C567FFM96477FCEP0S3FBKCL9
Ronnie wanted us to miss that one in the name of Team Spirit
LOL
False & misleading statements ?
Sanofi & Stallergenes where commercial partners
How did that work out ?
If Stallergenes picks up the Anergis assets they don't have to report if b/c they are private. If BP picks them up, we have to crawl threw a filing to find out ?
Seems everything this company does makes the stock price go down
What kinda political science is that from the puppet master ?
3 Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
https://www.sciencedirect.com/science/article/pii/S0923753420344963
https://clinicaltrials.gov/ct2/show/NCT02947854
Mission accomplished
We knew what he would do
How petty
Lemon juice
I bet Dr S doesn't know he could be posting on Yahoo
but he will
If successful, this approach could provide an entirely new set of tools for vaccine development.”
Press Release: Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform | Vir
https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-initiation-phase-1-clinical-trial
A Prototype Human CMV-based Vaccine
So, it's competitive to Mymx's delivery
https://clinicaltrials.gov/ct2/show/NCT04725877
26 trial participants. Estimated study completion date JANUARY 2025. What a nightmare.
https://clinicaltrials.gov/ct2/show/NCT01084343
24 participants
Phase IA. Now Kempers uses Phase II should start in the filings. That should be Phase IA / B
False & misleading statements ?
Lawsuit coming ?
RK has done this on purpose
& it's going to work
:}
Director Global Communications
I can't stop laughing
Many thanks
The good doctor
will never be where I was this weekend
Yes sir, founder Marcaurd Family Office Latin American
They are in it for the poor until da belly hits the floor
LOL
Insolvency proceedings
Entry Deadline: 18/07/2022
https://www.northdata.com/Anergis+SA,+Epalinges/CHE-109.310.720
Setting the deadline gives the foreign creditor a reasonable time to file a proof of claim & WJFS is a foreign creditor
https://lungpacer.com/company/bob-donohue/
Must be something worth fighting for, so might as well list Robert Donohue, the creditor, as Amy Wyss the creditor also
https://www.influencewatch.org/non-profit/lor-foundation/
:}
Anergis S.A. in liquidation, in Epalinges, CHE-109.310.720 (FOSC of 27.08.2021, p.
0/1005279410). By decision of the District Court of Lausanne of
12.05.2022, the company was declared bankrupt with effect from 12.05.2022, at 11.25 a.m.
Bankruptcies of the district of Lausanne
no information can be given over the phone
Chemin du Trabandan 28
1014 Lausanne Adm cant VD
https://tel-search-ch.translate.goog/lausanne-adm-cant/chemin-du-trabandan-28/des-faillites-de-larrondissement-de-lausanne-2.fr.html?_x_tr_sl=fr&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Of course not
LOL
https://www-vd-ch.translate.goog/themes/economie/poursuites-et-faillites/procedure-de-faillite/?_x_tr_sl=fr&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Lausanne District Bankruptcy Office
https://www-vd-ch.translate.goog/toutes-les-autorites/ordre-judiciaire-vaudois-ojv/offices-des-faillites/lausanne/?_x_tr_sl=fr&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Diagram of the bankruptcy procedure
https://www.vd.ch/fileadmin/user_upload/themes/economie_emploi/poursuites_faillites/Flowcharts/Fichiers_pdf/Procedure_de_faillite.pdf
For anyone who has spree laying around LOL
https://www-vd-ch.translate.goog/themes/economie/poursuites-et-faillites/ventes/recherche-dobjets/?_x_tr_sl=fr&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Those who hold the bankrupt's property, in whatever capacity, are required to make it available to the point of contact within the same period under threat of the penalties provided for by law
They will be stripped of their right of preference, unless there is sufficient excuse.
The point of contact indicated also applies to interested parties living abroad
Contact point: Lausanne District Bankruptcy Office, Chemin du Trabandan 28, 1006 Lausanne
Deadline: 1 month End of deadline: 18.07.2022
https://www.vd.ch/toutes-les-autorites/ordre-judiciaire-vaudois-ojv/offices-des-poursuites/lausanne/
https://www.vd.ch/recherche/tout/?q=Anergis&importantMessage=
Apparently Hosang Markus doesn't want to be a director
of a bankrupt company now
Seattle, we have a problem
LOL
https://biomedvc.com/en/team/investment-team/dr-markus-hosang
Sure looking forward to them naming Amy Wyss as a creditor
:}
On a positive note, Ronnie may finally get to shine sometime between now & Oct, b/c we are due Hiv data in October, knowingly or not, meaning November matters as does the bod meeting in Dec if there is one.....!!!!!!!
Go Biopole ?
& Baylor ?
& Bern ?
& Amsterdam ?
& Hzi ?
for revolutionizing pre-clinicals
ROTFLOL
So, the Anergis June 17, 2022 is a change
https://www.moneyhouse.ch/en/company/anergis-s-a-en-liquidation-12078807391/messages
Nice snag by you & the others...!!!!!!
Oh & Mr Kempers, a thanks to him on the heads up I guess
LOL
As of March 31, 2022, the Company is working on several research projects for immunotherapy in the field oncology
One of these projects started in May 2020, which is a research project with IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology. Due to Covid-19 restrictions, the study was delayed and further collaboration is currently not yet planned.
https://www.otcmarkets.com/filing/html?id=15814217&guid=eA1-kpTaeC7fJth
As of December 31, 2021, the Company is working on several research projects with commercial partners for immunotherapy in the field oncology
https://www.otcmarkets.com/filing/html?id=15702420&guid=eA1-kpTaeC7fJth
One could also look @ it as Anergis has been in liquidation for years now being
Beltrami Consluting
Chapter 7 bankruptcy is sometimes called liquidation bankruptcy
Dr. Hirth IO Biotech has served as Chairman of our board of directors since September 2016.
https://www.iobiotech.com/team/peter-hirth-ph-d/
Here he is w/ Grant
https://vaxcyte.com/about-us/
Pg 1
https://www.sec.gov/Archives/edgar/data/1865494/000119312521300173/d180178ds1.htm
Frank F. Rahmani & I won't get into Latham & Watkins again
PARTNER
Frank Rahmani
Capital Markets
Emerging Companies and Venture Capital
M&A
Private Equity
FRAHMANI@SIDLEY.COM
PALO ALTO +1 650 565 7050
SAN FRANCISCO +1 415 772 1276
https://www.sidley.com/en/people/r/rahmani-frank
Sidley Welcomes Life Sciences Corporate Partner Frank Rahmani in Palo Alto
https://www.sidley.com/en/newslanding/newpressreleases/2020/05/sidley-welcomes-life-sciences-corporate-partner-frank-rahmani-in-palo-alto
https://www.sidley.com/en/us/
Here is who Frank works for
https://www.sidley.com/en/us/ourstory/ourstorieslanding/conversation-with-martin-wellington/
Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines, in its US$287.5 million initial public offering.
https://www.sidley.com/en/people/f/fleming-carlton
Sidley Adds Cooley Corporate Partner In San Francisco
Fleming helped pharma company Vaxcyte Inc. go public at
https://www.law360.com/articles/1387829/sidley-adds-cooley-corporate-partner-in-san-francisco
Now about those Ernie Stern comments from Palo Alto
As of June 30, 2022, the Company is working on several research projects for immunotherapy in the field oncology
Have a good one folks
Time to shine Ronnie
You don't take that time line
Success is @ hand
Beyond that, GLORY
:}
Insiders won't get the notes in Sept
So the price does matter
Let's hear it for the Biotech consulting firms being two
One in Biopole is my guess b/c Ronnie is no salesman
Who is the other ?
Breslin
or
Mymetics Corp has retained Lazard as its financial advisor w/ Christian Rochet
Maybe it isn't Grant Pickering we need back
LOL
We know who MSD, Roche and Merck Serono, TS & JW are but the question you asked, Matrix is Matrix-M imho Who owns it Novavax :}
Note that Maria B has a study on Matrix-M as well
The below that you or SP1 had posted
UNPREDICTED TURNS
MY STORY
When a headhunter asked me to join the bioanalytical group for immuno- and bioassays at Triskelion, a Dutch CRO, I said yes.
https://scipotconsultancy.com/my-story
Triskelion History
https://www.triskelion.nl/history/
Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability
lipids and 3D-PHAD®, were analyzed by TNO Triskelion
https://link.springer.com/article/10.1007/s11095-018-2453-y
Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
performed at TNO Triskelion
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672496/
Texas Biomed’s labs have been used to test vaccine and other medical treatments to ensure they are safe to progress to human clinical studies. It has also conducted preclinical studies for biotech company Novavax for what could be the fourth COVID-19 vaccine
https://webcache.googleusercontent.com/search?q=cache:pDdvw5reAgwJ:https://www.expressnews.com/news/local/article/San-Antonio-infectious-disease-expert-and-Texas-16044154.php+&cd=38&hl=en&ct=clnk&gl=us
Yw brother
Now Ronnie has to lay down w/ her
@ some point if I continue to do this
I'll reach out to to you
Ronnie's wife
Not to get personal but
Someone gets shares in September
:}
B is also so done for weeks now
C is 8 to 10 weeks from there
:}
Seems Dr. Thomas Staehelin & Swiss Rockets
may have that 37:10 thing figured out meaning Batavia Biosciences does
Surely Ronnie knows that
LOL
It's a benefit to Mymx I take it
Dr. Susan Barnett is a Senior Program Officer at the Bill & Melinda Gates Foundation
http://www.multivivax.eu/who-we-are/independent-advisers/susan-barnett/
Hester Kuipers
Executive Director, Europe at International AIDS Vaccine Initiative (IAVI)
Amsterdam, North Holland, Netherlands
16 years 4 months
Executive Director, Europe
Aug 2014 - Present7 years 11 months
Amsterdam Area, Netherlands
https://nl.linkedin.com/in/hester-kuipers-4115848
Pepe Alcamí
Who is reading the papers Ronnie ?
https://www.fls-science.com/fls-speakers/jose-alcami/#:~:text=Dr%20Jos%C3%A9%20(Pepe)%20Alcam%C3%AD%20(,the%20Spanish%20AIDS%20Research%20Network.
Professor Robin Shattock
Faculty of Medicine, Department of Infectious Disease
Chair in Mucosal Infection and Immunity
Contact
+44 (0)20 7594 5206
Email
Location
453
Wright Fleming Wing
St Mary's Campus
Summary
Professor Robin Shattock is the Head of Mucosal Infection and Immunity within the Department of Medicine at Imperial College London. Professor Shattock’s research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. This has led to the establishment of international collaborations aimed at preclinical identification, development and selection of HIV microbicide and vaccine candidates prior to formal clinical efficacy trials.
Professor Shattock oversees a portfolio of research that is supported by 26 members of staff including researchers, PhD students, clinical trial managers and project managers. Professor Shattock has published over 160 peer reviewed articles in this area and secured funding from the European Commission, Bill and Melinda Gates Foundation, Wellcome Trust, MRC and the NIH.
DNAVAC is funded by the Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD). Prof Shattock’s group is responsible for the DNAVAC project (https://www.cavd.org/grantees/Pages/Grantee-Shattock.aspx) which aims to apply recent state of the art technological advances in DNA vaccination and immune monitoring, both at the single cell and molecular level, to enable detailed probing of developing vaccine induced antibody responses.
ADITEC (Advanced Immunisation Technologies: http://www.aditecproject.eu) is funded under the 7th Framework by the EU. ADITEC is a collaborative research programme with 42 partners from 13 EU countries that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Professor Shattock leads the Prime-boost workpackage for the consortium.
BioVacSafe (Biomarkers for enhanced vaccines immunosafety - http://www.biovacsafe.eu) is a 5 years project funded by EU Innovative Medicine initiative (IMI). BioVacSafe aims to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. It is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO): http://www.biovacsafe.eu/#sthash.UN2RSrBe.dpuf. Professor Shattock leads the work package on preclinical models.
The EAVI2020 consortium, funded under H2020 by the EU, is led by Prof Shattock at Imperial College London, and brings together leading HIV researchers from 23 public organisations and biotech companies from across Europe, Australia, Canada and the USA, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. http://www.eavi2020.eu. In addition to coordinating the programme, Prof Shattock’s group is responsible for performing a range of Experimental Medicine clinical trials of promising new HIV candidates.
https://www.imperial.ac.uk/people/r.shattock
Interesting Mucosal discussion @ 37:10
and Hans Langedijk for inspirational discussions.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945883/
This session included a presentation by Rogier Sanders (Academisch Medisch Centrum) on Novel envelope proteins to induce neutralizing antibodies.
https://www.eavi2020.org/opportunities-and-obstacles-for-hiv-vaccines-eavi2020-at-the-9th-ias-conference-on-hiv-science-23-26-july-2017/
Current position
Research Director
https://www.researchgate.net/profile/Johannes-Langedijk
& Galit Alter
In the 3rd link in today's first post from the first link in that one
& so much more
Dr. Gabriella Scarlatti
From the video in last link
1-HSR:
For Scientific matters
Dr. Gabriella Scarlatti
Viral Evolution and Transmission Unit
DIBIT — Fondazione Centro San Raffaele del Monte Tabor
Via Olgettina 58, 20132 Milan, Italy
Tel: 0039 022643 4906 (dir) or 2821 (Assistant)
Email:scarlatti.gabriella@hsr.it
https://www.sec.gov/Archives/edgar/data/927761/000095015208001236/l30222aexv10w1.htm
& Margaret E Ackerman
https://biomedicalsciences.unimelb.edu.au/__data/assets/pdf_file/0011/3162719/281Lewisfimm.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168074399
Happy Juneteenth 2022
Getting closer to an HIV/AIDS vaccine
NEWS ARTICLE 18 May 2022
https://hadea.ec.europa.eu/news/getting-closer-hivaids-vaccine-2022-05-18_en
https://www.ehv-a.eu/index.php
https://www.ehv-a.eu/partners#
My, does google ever got it bad here
https://www.eavi2020.org/partners/
What’s next for an HIV vaccine?
28th April 2022
https://www.eavi2020.org/whats-next-for-an-hiv-vaccine/
LOL
Echoing the both of you
No pr for 2 years come Nov
I don't think Rk & the insiders will do us wrong
Happy Fathers Day to all that are & what comes w/ that
It's a great group of folks we have here.....!!!!!!
Fits the Breslin template, doesn't it
It also fits what AhsokaXC wanted to know, so 10 weeks
What's important is also what AhsokaXC picked out in the 10Q
What Mr K said, most missed that is important
b/c the Nih does not fund phase I trails that I know of
It also fits the current price that I gave everyone
It's always been a case of less is more imho
Take it down & I'll own them
Later brother, transparency rules
Santangelo ?
https://academicmedicaleducation.com/philip-santangelo-phd
https://bme.gatech.edu/bme/news/santangelo-using-nih-grant-prevent-hiv-women
Georgia Institute of Technology and Emory University
https://sites.gatech.edu/santangelo/
https://www.facebook.com/GTengineering/videos/hiv-preventatives-with-phil-santangelo/2447562682036841/?_rdr